This program project application focuses on the treatment of solid tumors using immunotherapeutic approaches. All four projects will include clinical trials as a component of the studies that require a GMP manufacturing facility for the preparation of clinical grade vectors and cellular therapy products. The GMP Facilities at the Center for Cell and Gene Therapy have been in operation for more than 13 years and have recently relocated to one of the largest and most modern academic facilities of its type. The Cell Processing Facility (CPF) has considerable experience in the preparation of a wide variety of cellular products, including all that would be prepared for the proposed projects. The CPF has been designated one of five National Somatic Cell Therapy Processing Facilities by the NHLBI under its Production Assistance for Cell Therapy Contract (PACT) Program. The Vector Production Facility (VPF), which is also be part of the Core, has produced more than 50 clinical grade viral vectors for local, national and international studies and was a National Gene Vector Laboratory for adenoviral vectors. It also has considerable experience in manufacturing clinical grade master and working cell banks. The final components of the Core are the Quality Control Laboratory, which performs in-house testing of cellular products and vectors, and is responsible for environmental monitoring of the GMP areas;and the Quality Assurance Group that ensures compliance with GMP regulations and provides independent overview of all aspects of product manufacturing, testing, release and distribution. The GMP staff also have extensive regulatory experience that will facilitate the translational of laboratory studies into clinical trials. In summary, the Cell Processing and Vector Production Core will provide all of GMP-grade therapeutic products for the proposed clinical studies that are vital components of this application.

Public Health Relevance

The goal of this core is to manufacture, in a safe manner with appropriate quality control, all of the vectors and cells that will be administered to patients on the proposed clinical trials that are part of every component project

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA094237-12
Application #
8933458
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (O1))
Program Officer
Merritt, William D
Project Start
2014-02-01
Project End
2018-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
12
Fiscal Year
2014
Total Cost
$478,502
Indirect Cost
$172,265
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Heslop, Helen E; Brenner, Malcolm K (2018) Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther 26:1-2
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Kalra, Mamta; Gerdemann, Ulrike; Luu, Jessica D et al. (2018) Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy :
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Lyon, Deborah; Lapteva, Natasha; Gee, Adrian P (2018) Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Mol Ther 26:6-7
Shum, Thomas; Kruse, Robert L; Rooney, Cliona M (2018) Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther 18:653-664
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
McLaughlin, Lauren P; Rouce, Rayne; Gottschalk, Stephen et al. (2018) EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 132:2351-2361
Mata, Melinda; Gerken, Claudia; Nguyen, Phuong et al. (2017) Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. Cancer Discov 7:1306-1319
Tzannou, Ifigeneia; Papadopoulou, Anastasia; Naik, Swati et al. (2017) Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol 35:3547-3557

Showing the most recent 10 out of 217 publications